title: [What opportunities does Immuno-oncology indicate for overarching long-term survival?].
authors.affiliation: Medizinische Klinik II: Hämatologie/Onkologie, Universitätsklinikum Frankfurt, Frankfurt/M., Deutschland.
authors.forename: Lothar
authors.initials: L
authors.lastname: Bergmann
authors.forename: Wolfram
authors.initials: W
authors.lastname: Brugger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Herr
authors.forename: Andreas
authors.initials: A
authors.lastname: Mackensen
authors.forename: Gabriele
authors.initials: G
authors.lastname: Multhoff
mesh_terms: D000951:Antigens, Neoplasm / Q000502:physiology; D060908:CTLA-4 Antigen / Q000502:physiology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D061026:Programmed Cell Death 1 Receptor / Q000502:physiology; D013601:T-Lymphocytes / Q000502:physiology
chemical_list: D000951:Antigens, Neoplasm; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor